Back

Safety, tolerability and blood pressure lowering of the innovative guanylyl cyclase a-receptor activator MANP in an ethnically diverse resistant hypertension population: a phase 1B clinical trial

30 August 2024 (14:40 - 14:50)
Organised by: Logo
Congress Presentation Part of: Pharmacological management of hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Horng Chen

Mayo Clinic, Rochester (United States of America)

5 More presentations in this session

Presentation thumbnail
Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive
Doctor M. Saxena (London, GB)
Abstract Slides Video
Presentation thumbnail
Antihypertensive treatment of masked hypertension guided by ambulatory blood pressure monitoring: a double-blind, placebo-controlled trial
Doctor D. Zhang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers vs. calcium channel blockers for 12,478 young hypertensive patients under 40 in 10-year follow-up
Doctor S. Jo (Anyang-Si- Gyeonggi-Do, KR)
Abstract Slides Video
Presentation thumbnail
Blood pressure lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of 500 randomised, double-blind placebo-controlled trials
Doctor N. Wang (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Antihypertensive treatment during pregnancy and maternal and fetal outcomes
Professor J. Vaclavik (Ostrava, CZ)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacological management of hypertension
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 14:40 CET
You may be interested in
thumbnail
Congress Session
Pharmacological management of hypertension
thumbnail
Congress Presentation
Hot papers on drugs for hypertension
thumbnail
Congress Presentation
BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources